Halberd’s COVID-19 Antibody is the Only One In Competitive Tests to Bind to Omicron Variant
Outperforms Approved COVID Antibodies Jackson Center, PA, March 1, 2022 – Halberd Corporation’s (OTC PINK:HALB) previously developed SARS-CoV-2 antibody demonstrated superior binding capability to the SARS-CoV-2 Omicron variant disease antigen. The Halberd antibody was tested against monoclonal antibodies which are biosimilar to five FDA approved Emergency Use Authorization (EUA) COVID antibodies. The results are shown ...